TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In the phase III PREVAIL trial, adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis had improved symptom scores with investigational gefurulimab, given as a weekly under-the-skin injection. The reported results showed improvement within one week and a safety profile generally similar to placebo, but the supplied report does not give the trial’s size, full results, or regulatory status.
Adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis had improved symptom scores in the phase III PREVAIL trial of investigational gefurulimab, according to findings presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting. The treatment is a once-weekly subcutaneous injection; trial results also indicated improvement could begin quickly, while its safety profile was generally comparable to placebo.
PREVAIL was described as a double-blind, placebo-controlled trial. The report said gefurulimab met its primary outcome on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale. The reported change was a 4.2-point reduction with gefurulimab compared with a 2.1-point reduction with placebo; the difference was statistically significant. The source does not provide the number of participants or the precise analysis time point for these figures.
The report also describes a rapid response: MG-ADL improvement was statistically significant within one week, and improvement on the Quantitative Myasthenia Gravis measure was reported at four weeks. The article does not include detailed score changes for that second measure or a full account of how long benefits lasted.
Adverse events were reported as similar overall between the treatment and placebo groups. Injection-site reactions were somewhat more frequent with gefurulimab and were described as mild to moderate. Headache, upper respiratory infections, and muscle aches and pains were among the common events. No meningococcal infections were reported in the trial; participants were vaccinated, and those starting treatment before two weeks after vaccination received antibiotics, according to the clinician interviewed.
A Weekly Injection May Ease Treatment
The result could matter to people managing generalized myasthenia gravis because the proposed treatment schedule may reduce the need for infusion-center visits. James Winkley, a physician at Baptist Health Medical Group in Lexington, Kentucky, said the smaller molecule can be administered under the skin once a week. That could offer a different practical option from treatments requiring intravenous infusions, although the trial results alone do not establish that patients will experience better access or quality of life in routine care.
Winkley also said gefurulimab was studied alongside stable IVIG therapy, a treatment sometimes used in myasthenia gravis. He described compatibility with IVIG as a possible advantage because it may allow some patients to use the treatments together without supplemental dosing. The supplied report does not detail how many participants received IVIG or provide enough data to establish how broadly this combination can be used.
Products Worth Considering
EGO POWER+ 16-Inch POWERLOAD String Trimmer with Telescopic Carbon Fiber Shaft (Battery and Charger Not Included)
Greenworks 48V (2 × 24V) 20-Inch Brushless Cordless Push Lawn Mower with Two 4.0Ah Batteries and Dual-Port Charger
Garvee 6x8ft Walk-in Greenhouse with Aluminum Frame and Polycarbonate Panels
As an affiliate, we earn on qualifying purchases.
How PREVAIL Fits Current Treatment
Myasthenia gravis is a neuromuscular disorder that can cause fluctuating weakness. The PREVAIL findings concern a specific group: adults with generalized disease and anti-acetylcholine receptor antibodies. They should not be assumed to apply to other forms of the condition or to every patient.
Winkley described gefurulimab as a complement inhibitor and compared its treatment approach with existing options, including eculizumab and ravulizumab. He said current choices vary in frequency and route, from daily medication to infusions delivered every two or eight weeks. The weekly injection would add another schedule for patients and clinicians to weigh; trial results do not establish which option is best for an individual.
“This would represent a greater ease of access for patients to have a [subcutaneous], once-a-week injection that doesn’t require them to go to the infusion center.”
— James Winkley, MD, of Baptist Health Medical Group, speaking to MedPage Today
Trial Details Still Missing
The available report does not state the trial enrollment, participant characteristics, follow-up duration, or full statistical results. It also does not provide detailed data on how many participants used IVIG, how durable symptom improvements were, or how the treatment performed across different patient groups. Those omissions limit what can be concluded from the reported score changes and safety summary.
The results are from a clinical trial presentation, not evidence in this source that gefurulimab has received regulatory approval or is available for routine treatment. Although no meningococcal infections were reported, that finding does not establish that the risk is absent; the report says participants were vaccinated and some received antibiotics. Further safety data and the complete trial findings are needed.
Full Results and Regulatory Review
The next useful information will be a complete account of PREVAIL’s design and results, including the participant count, duration of treatment and follow-up, detailed safety data, and outcomes for patients receiving IVIG. The supplied report does not give a date for publication or identify a next trial milestone.
Any decision about future availability depends on further development and regulatory review. Until more information is reported, the findings support cautious interest in a weekly injection option, not a conclusion that gefurulimab is approved, broadly suitable, or superior to existing treatments.
Key Questions
What is gefurulimab?
It is an investigational nanobody and complement inhibitor studied as a once-weekly injection under the skin for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
What did the PREVAIL trial report?
The phase III trial reported a statistically significant reduction in MG-ADL symptom scores: 4.2 points with gefurulimab versus 2.1 points with placebo. The source does not specify the analysis time point or include the full trial results.
How quickly did symptoms improve?
The report said a statistically significant MG-ADL reduction was seen within one week. It also reported improvement on the Quantitative Myasthenia Gravis measure at four weeks, without giving the detailed results for that measure.
What safety findings were reported?
Overall adverse events were described as similar to placebo. Injection-site reactions were somewhat more frequent with gefurulimab and were generally mild to moderate; headaches, upper respiratory infections, and muscle aches and pains were also reported. No meningococcal infections occurred in the trial, whose participants were vaccinated and, in some cases, given antibiotics.
Is gefurulimab approved or available?
The supplied report describes trial findings and does not say that gefurulimab is approved or available for routine treatment. Its regulatory status and next development steps are not specified.
Source: medpagetoday.com
